La maladie de Parkinson au Canada (serveur d'exploration) - Merge (Accueil)

Index « Auteurs » - entrée « James B. Koprich »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
James B. Johnston < James B. Koprich < James B. Leverenz  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000127 (2017) Chi Wang Ip [Allemagne] ; Laura-Christin Klaus [Allemagne] ; Akua A. Karikari [Allemagne] ; Naomi P. Visanji ; Jonathan M. Brotchie ; Anthony E. Lang ; Jens Volkmann [Allemagne] ; James B. KoprichAAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
000138 (2016) Naomi P. Visanji [Canada] ; Jonathan M. Brotchie [Canada] ; Lorraine V. Kalia [Canada] ; James B. Koprich [Canada] ; Anurag Tandon [Canada] ; Joel C. Watts [Canada] ; Anthony E. Lang [Canada]α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
000153 (2016) Qing He [République populaire de Chine] ; James B. Koprich [Canada] ; Ying Wang [République populaire de Chine] ; Wen-Bo Yu [République populaire de Chine] ; Bao-Guo Xiao [République populaire de Chine] ; Jonathan M. Brotchie [Canada] ; Jian Wang [République populaire de Chine]Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
000157 (2016) James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; Gabriela Reyes [Canada] ; Vanessa Omana [Canada] ; Jonathan M. Brotchie [Canada]Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
000552 (2015) Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada]Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
000879 (2014) Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
000C48 (2013) Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. BrotchieThe pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
000C55 (2013) James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. BrotchieThe effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
000F21 (2013) Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque
001047 (2013) Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque
001051 (2013) James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada]The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
001215 (2012) Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. BrotchieL-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
001676 (2011) James B. Koprich ; Tom H. Johnston ; Philippe Huot ; M. Gabriela Reyes ; Maria Espinosa ; Jonathan M. BrotchieProgressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
001854 (2011) James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada]The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
001991 (2011) James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada]The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease
001B55 (2010) James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; M Gabriela Reyes [Canada] ; Xuan Sun [Canada] ; Jonathan M. Brotchie [Canada]Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i -k "James B. Koprich" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i  \
                -Sk "James B. Koprich" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    Author.i
   |clé=    James B. Koprich
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022